- Herpes treatment options, encompassing antiviral drugs and supportive therapies, have become essential components of managing herpes simplex virus (HSV) infections globally. These therapies are increasingly sought after due to rising prevalence, recurrent outbreaks, and the long-term nature of the infection, which often requires lifelong management in both genital and oral herpes cases
- The growing demand for herpes treatment is primarily fueled by the rising incidence of HSV infections worldwide, increased awareness about sexually transmitted diseases (STDs), improved access to diagnostic tools, and the expanding availability of novel treatment formulations, including extended-release antivirals and topical therapies
- North America dominated the herpes treatment market, capturing the largest revenue share of 42.6% in 2024, owing to high disease prevalence, early availability of branded antiviral drugs, increased awareness and screening, and the presence of major pharmaceutical companies such as GlaxoSmithKline and Pfizer
- Asia-Pacific is projected to be the fastest-growing region in the herpes treatment market, with a CAGR of 7.9% from 2025 to 2032, driven by increasing STD awareness campaigns, growing population, rising healthcare expenditure, and improving diagnostic capabilities in countries such as China, India, and Japan
- The herpes simplex segment dominated the herpes treatment market with a market share of 68.5% in 2024. This is due to its higher prevalence worldwide and the chronic nature of infections requiring ongoing treatment and management, compared to Herpes Zoster which generally affects older populations
